Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
General transcription factor IIi pseudogene 20 (GTF2IP20) is classified as a human pseudogene. Pseudogenes are gene sequences similar to known genes but are typically nonfunctional due to mutations or lack of regulatory elements required for expression. There are no data supporting that GTF2IP20 encodes a functional protein, is expressed in any tissue, or has been implicated as a therapeutic or biological target in any disease. It should not be confused with GTF2I, the functional general transcription factor IIi, which does have key roles in transcription regulation, immune signaling, and neurological development, and is sometimes involved in disease [5][1][2][3]. Key note: GTF2IP20 (Gene ID: 441124) is a pseudogene and not equivalent to GTF2I, a functional gene with described biological activity and disease relevance. Any confusion likely arises from the similarity in names, but GTF2IP20 does not have protein, functional, or clinical target status [5][1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on General transcription factor IIi pseudogene 20 (GTF2IP20).